SCHEMBL7204290

SCHEMBL7204290

O=C(NO)C1(O)CNCCC1S(=O)(=O)N1CCC(c2ccccc2Cl)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 6/20 0.46
MMP13 P45452 5/20 0.46
ADAM10 O14672 4/20 0.40
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC10 Q969S8 1/20 0.36
HDAC11 Q96DB2 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
HDAC9 Q9UKV0 1/20 0.36
HDAC5 Q9UQL6 1/20 0.36
MMP1 P03956 2/20 0.35
POLB P06746 1/20 0.35
HTT P42858 1/20 0.35
ADAMTS4 O75173 1/20 0.35
ADAM17 P78536 1/20 0.34
FAAH O00519 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7205516 0.88 ADAM10 (0.51) MMP2MMP13ADAM10HDAC4MMP1
SCHEMBL7201770 0.88 MMP2 (0.44) MMP2MMP13ADAM10HDAC4MMP1
SCHEMBL7201786 0.85 MMP2 (0.49) MMP2MMP13ADAM10
SCHEMBL7201610 0.85 MMP2 (0.47) MMP2MMP13ADAM10HDAC6MMP1
SCHEMBL7201026 0.83 HTR2C (0.48) EPHX2
SCHEMBL7205407 0.83 MMP13 (0.52) MMP2MMP13ADAM10MMP1ADAMTS4
SCHEMBL7199659 0.82 HSD11B1 (0.39) MMP2MMP13ADAM10MMP1ADAM17
SCHEMBL7200507 0.81 MMP13 (0.45) MMP2MMP13MMP1ADAMTS4ADAM17
SCHEMBL7204534 0.79 USP5 (0.41) MMP2MMP13ADAM10
SCHEMBL7205659 0.79 TP53 (0.41) MMP2MMP13ADAM10MMP1ADAM17

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608104-B2 Antiarthritic agents; anticancer agents PFIZER INC 2003-08-19 US disclosed
US-20020019534-A1 Gem substituted hydroxamic acids PFIZER INC. 2002-02-14 US disclosed
EP-1138680-A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors Pfizer Products Inc. (US) 2001-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019534-A1 Gem substituted hydroxamic acids MMP14, TOP2A, ADAMTS1 MMP2 13/4885MMP13 4/4885ADAM10 254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.